A Phase 2 interventional study of Placebo and M2951 in Systemic Lupus Erythematosus, sponsored by EMD Serono Research & Development Institute, Inc.. Terminated at 157 sites in 19 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-12.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).
1,207 studies on the registry are indexed under Lupus Erythematosus, Systemic; 405 are open to participants now.
This study's enrollment of 469 is above the median of 52 across 876 interventional studies indexed under Lupus Erythematosus, Systemic.
Browse Lupus Erythematosus, Systemic studies →EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: M2951
Drug: M2951
Drug: M2951
Drug: M2951
Drug: M2951
Drug: M2951
Drug: M2951
Participants received placebo matched to M2951 orally for 52 weeks.
Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.
Also known as: Evobrutinib
Participants received 75 mg of M2951 orally QD for 52 weeks.
Also known as: Evobrutinib
Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
Also known as: Evobrutinib
Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
Also known as: Evobrutinib
DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52
SRI-4 response was defined as greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE) divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor).
Time frame: Week 52
DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6) at Week 52
SRI-6 response was defined as \>= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor).
Time frame: Week 52
DBPC Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: events between first dose of study drug that were absent before treatment/that worsened relative to pre-treatment state up to 56 weeks. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.
Time frame: Baseline up to Week 56
DBPC Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs by severity were reported.
Time frame: Baseline up to Week 56
DBPC Period: Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.
Time frame: Baseline up to Week 56
DBPC Period: Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings
12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. The corrected QT interval (QTcF) was calculated using Fridericia's formula. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.
Time frame: Baseline up to Week 56
DBPC Period: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.
Time frame: Baseline up to Week 56
DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 2
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 2.
Time frame: Week 2
DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 4
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 4.
Time frame: Week 4
DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 12
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 12.
Time frame: Week 12
DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 24
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 24.
Time frame: Week 24
DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 36
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 36.
Time frame: Week 36
DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 52
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 52
Time frame: Week 52
DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 56
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 56
Time frame: Week 56
DBPC Period: Mean Absolute Total B Cell Count at Week 4
Mean total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts.
Time frame: Week 4
DBPC Period: Mean Absolute Total B Cell Count at Week 24
Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts.
Time frame: Week 24
DBPC Period: Mean Absolute Total B Cell Count at Week 52
Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts.
Time frame: Week 52
DBPC Period: Mean Absolute Total B Cell Count at Week 56
Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts.
Time frame: Week 56
DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 2
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline and Week 2
DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 4
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline and Week 4
DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 12
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline and Week 12
DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 24
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline and Week 24
DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 36
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline and Week 36
DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 52
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline and Week 52
DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 56
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline and Week 56
DBPC Period: Change From Baseline in Total B Cell Count at Week 4
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.
Time frame: Baseline and Week 4
DBPC Period: Change From Baseline in Total B Cell Count at Week 24
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.
Time frame: Baseline and Week 24
DBPC Period: Change From Baseline in Total B Cell Count at Week 52
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.
Time frame: Baseline and Week 52
DBPC Period: Change From Baseline in Total B Cell Count at Week 56
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.
Time frame: Baseline and Week 56
DBPC Period: Time to First Severe British Isles Lupus Assessment Group (BILAG) A Flare
BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity. Time to first severe flare, where a severe flare is defined as at least one BILAG A (Severe disease activity) score in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52-Week Treatment. It was measured using Kaplan-Meier (KM) estimates.
Time frame: Baseline up to Week 56
DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52 in Serologically Active (SA) Subgroup
SRI-4 response was defined as greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor).
Time frame: Week 52
DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6) at Week 52 in Serologically Active Subgroup
SRI-6 response was defined as \>= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from 0(very well) to 100(very poor).
Time frame: Week 52
DBPC Period: Time to First British Isles Lupus Assessment Group (BILAG) A or 2B Moderate to Severe Flare
BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity. A Moderate to Severe (BILAG A or 2B) flare is defined as at least one BILAG A (severe disease activity) grade or two BILAG B (moderate disease activity) grade in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52 week treatment. It was measured using Kaplan-Meier (KM) estimates.
Time frame: Baseline up to Week 56
DBPC Period: Number of Participants With British Isles Lupus Assessment Group (BILAG) 2004 Flare-Free Status During the 52-Week Treatment Period
A participant has a flare-free status if no flare has been reported during the 52-week treatment period. Participants who discontinued treatment prior to Week 52, without having a flare are counted as not being flare free at Week 52. A flare was defined as either 1 or more new BILAG-2004 A (severe disease activity) or 2 or more new BILAG-2004 B (moderate disease activity) items compared to the previous visit. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected.
Time frame: up to Week 52
DBPC Period: Annualized Flare Rate
A flare was defined as either 1 or more new BILAG-2004 A (severe disease activity) or 2 or more new BILAG-2004 B (moderate disease activity) items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG 2004 assessment.
Time frame: Baseline up to Week 52
DBPC Period: Number of Participants With Low Disease Activity Status, Defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score of Less Than or Equal (<= ) 2 at Week 52
Low disease activity is defined as SLEDAI-2K score \<=2. SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).
Time frame: Week 52
DBPC Period: Number of Participants With Low Disease Activity Status, Defined by Clinical Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score of Less Than or Equal (<= ) 2 at Week 52
Low disease activity is defined as SLEDAI-2K score \<=2. SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). Clinical SLEDAI-2K score is equal to the SLEDAI-2K score from electronic case report form (eCRF) excluding the components 'Increased Deoxyribonucleic acid (DNA) Binding' and 'Low Complement'.
Time frame: Week 52
DBPC Period: Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).
Time frame: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
DBPC Period: Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
CLASI is an validated measurement instrument for lupus erythematosus developed for use in clinical studies that consists of separate scores for the activity of the disease (CLASI-A). The CLASI activity score is calculated on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI activity score ranges from 0-70, with higher scores indicating more severe skin disease. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70).
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
DBPC Period: Number of Participants With Response Based on BILAG-Based Composite Lupus Assessment (BICLA) at Week 52
BICLA response defined as participants meeting following criteria: \[1\] At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry (example: all A (severe disease) scores falling to B (moderate), C (mild), or D (no activity) and all B scores falling to C or D; \[2\] No new BILAG A or more than one new BILAG B scores; \[3\] No worsening of total SLEDAI-2K score from baseline; \[4\] No significant deterioration (=\<10%) in physician's global assessment and \[5\] No treatment failure (initiation of non-protocol treatment).
Time frame: Week 52
DBPC Period: Change From Baseline in British Isles Lupus Assessment Group (BILAG)-2004 Score at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
BILAG 2004 disease activity Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity.
Time frame: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
DBPC Period: Change From Baseline in Physician's Global Assessment (PGA) Score at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
The Physician's Global Assessment of Disease Activity was recorded using the 100 millimeter horizontal Visual Analog Scale (VAS). Physician rated participant's disease activity on a scale ranged from 0-100 millimeter (mm), where 0 indicated no disease activity and 100 represented maximum disease activity.
Time frame: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
DBPC Period: Change From Baseline in Study 36-Item Short Form Health Survey Version 2 (SF-36v2) Physical Component Summary Score and Mental Component Summary Scores at Week 4, 8, 12, 16, 24, 32, 40 and 52
The 36-Item Short-Form Health Survey (SF-36) was a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) was based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0 - 100 (100 = highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100 = highest level of physical functioning).
Time frame: Baseline, Week 4, 8, 12, 16, 24, 32, 40 and 52
DBPC Period: Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire at Week 4, 8, 12, 16, 24, 32, 40 and 52
The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (perfect health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
Time frame: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52
DBPC Period: Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) at Week 4, 8, 12, 16, 24, 32, 40 and 52
The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. The responses were used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 was the worst health you can imagine and 100 was the best health you can imagine.
Time frame: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52
DBPC Period: Change From Baseline in Lupus Quality of Life (LupusQoL) Questionnaire Score at Week 4, 8, 12, 16, 24, 32, 40 and 52
The Lupus QoL assessment is a 34 item questionnaire across 8 domains that is designed to find out how systemic lupus erythematosus (SLE) affects a participant's life. Domains include physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Participants indicate their responses on a 5-point Likert response format, where 4=never, 3=occasionally, 2= a good bit of the time, 1=most of the time, and 0=worst of the time. Summary scores can be calculated for all 8 domains. A LupusQoL score for each domain was reported on a 0 to 100 scale, with greater values indicating better health related QoL.
Time frame: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52
DBPC Period: Number of Participants With Patient Global Impression of Change (PGIC) Scale Score of Any Improvement, no Change and Any Worsening
The PGIC is a self-rated scale that asks the participant to describe the change in activity limitations, symptoms, emotions, and overall quality of life (QoL) related to the participants painful condition on the following scale: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse). Number of participants in the PGIC categories of any improvement (that is PGIC scale score 1, 2 or 3), no change (that is PGIC scale score 4) and any worsening (that is PGIC scale score 5, 6 or 7) are reported.
Time frame: Week 4, 8, 12, 16, 24, 32, 40, and 52
DBPC Period: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 4, 8, 12, 16, 24, 32, 40 and 52
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status.
Time frame: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52
DBPC Period: Number of Participants With Change From Baseline in Prednisone Equivalent Corticosteroid (CS) Dose by >=25% to a Dose of <=7.5 Milligram Per Day (mg/Day), With no BILAG A or 2B Flare in Disease Activity at Week 52
BILAG A or 2B flare is defined as at least one BILAG A grade or two BILAG B grade in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52 week treatment period. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to systemic lupus erythematosus (SLE), divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected.
Time frame: Baseline and Week 52
DBPC Period: Change From Baseline to Week 52 in Prednisone Equivalent Corticosteroid (CS) Daily Dose at at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Baseline in Prednisone-equivalent CS Daily Dose at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 were reported.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
DBPC Period: Number of Participants With Reduction From Baseline in Prednisone Equivalent Corticosteroid (CS) Daily Dose by > 0 to 25%, >25% to 50%, >50% to 100% or an Increase at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Number of Participants With Reduction From Baseline in Prednisone-equivalent Corticosteroid (CS) Daily Dose by \> 0 to 25%, \>25% to 50%, \>50% to 100% or an Increase at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 were reported.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
DBPC Period: Cumulative Prednisone Equivalent Corticosteroid (CS) Dose at Week 52
Cumulative Prednisone-equivalent Corticosteroid (CS) Dose was calculated at Week 52.
Time frame: Week 52
DBPC Period: Number of Participants With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to 7.5 mg Prednisone Equivalent Per Day or Less With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52
SRI-4 response was defined as greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor).
Time frame: Week 52
DBPC Period: Number of Participants With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to 7.5 mg Prednisone Equivalent Per Day or Less With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6) at Week 52
SRI-6 response was defined as \>= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor).
Time frame: Week 52
DBPC Period: Number of Participants With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to 7.5 mg Prednisone Equivalent Per Day or Less With Response Based on SRI-4 at Week 52 in Serologically Active Subgroup
SRI-4 response was defined as greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from very well(0)-very poor(100).
Time frame: Week 52
DBPC Period: Number of Participants With Lupus Low Disease Activity State (LLDAS) at Week 52
Lupus low disease activity state will be measured as: SLEDAI-2K \<= 4; No activity in any major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever); No new features of disease activity compared with the previous assessment; Prednisone-equivalent \<= 7.5 milligram per day; Unchanged background immunosuppressive therapy.
Time frame: Week 52
A total of 1053 participants with Systemic Lupus Erythematosus (SLE) were screened. Out of which 469 participants were randomized in ratio of 1:1:1:1 to 1 of 4 treatment groups: Placebo; M2951 25mg QD, M2951 75 mg QD and M2951 50 mg BID. 283 out of 348 participants that completed Double-Blind Placebo-Controlled (DBPC) period, entered the Long-Term Extension (LTE) period of study.
| Milestone | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID | LTE: Placebo/ M2951 50 mg BID | LTE Period: M2951 25 mg QD/ M2951 50 mg BID | LTE Period: M2951 75 mg QD/ M2951 50 mg BID | LTE: M2951 50 mg BID/ M2951 50 mg BID |
|---|---|---|---|---|---|---|---|---|
| Started | 117 | 118 | 117 | 117 | 0 | 0 | 0 | 0 |
| Completed | 85 | 89 | 90 | 84 | 0 | 0 | 0 | 0 |
| Not completed | 32 | 29 | 27 | 33 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 16 | 17 | 13 | 18 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 2 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 1 | 3 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 4 | 2 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Premature termination of the study | 5 | 6 | 6 | 4 | 0 | 0 | 0 | 0 |
| Milestone | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID | LTE: Placebo/ M2951 50 mg BID | LTE Period: M2951 25 mg QD/ M2951 50 mg BID | LTE Period: M2951 75 mg QD/ M2951 50 mg BID | LTE: M2951 50 mg BID/ M2951 50 mg BID |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 62 | 69 | 80 | 72 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 62 | 69 | 80 | 72 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 7 | 4 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 55 | 63 | 76 | 72 |
SRI-4 response was defined as greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE) divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor).
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52 | 52 | 64 | 60 | 55 |
SRI-6 response was defined as \>= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor).
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6) at Week 52 | 22 | 27 | 30 | 24 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: events between first dose of study drug that were absent before treatment/that worsened relative to pre-treatment state up to 56 weeks. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Any TEAEs | 96 | 103 | 100 | 99 |
| Any serious TEAE | 10 | 13 | 11 | 9 |
Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs by severity were reported.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Grade 1 | 76 | 80 | 79 | 76 |
| Grade 2 | 63 | 77 | 72 | 78 |
| Grade 3 | 24 | 29 | 24 | 21 |
| Grade 4 | 1 | 1 | 0 | 2 |
| Grade 5 | 0 | 1 | 1 | 0 |
Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 | 0 | 0 |
12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. The corrected QT interval (QTcF) was calculated using Fridericia's formula. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings | 0 | 0 | 0 | 0 |
Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters | 0 | 0 | 0 | 0 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 2.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | 14.56 ± 5.367 | 13.75 ± 4.652 | 14.37 ± 5.536 | 12.81 ± 3.847 |
| IgA | 2.62 ± 1.207 | 2.75 ± 1.374 | 2.78 ± 1.328 | 2.66 ± 1.137 |
| IgM | 1.12 ± 0.662 | 1.22 ± 0.890 | 1.09 ± 0.697 | 1.18 ± 0.776 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 4.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | 14.92 ± 5.497 | 13.60 ± 4.590 | 14.21 ± 4.828 | 12.73 ± 3.771 |
| IgA | 2.71 ± 1.284 | 2.73 ± 1.349 | 2.82 ± 1.293 | 2.64 ± 1.109 |
| IgM | 1.12 ± 0.699 | 1.18 ± 0.824 | 1.06 ± 0.676 | 1.16 ± 0.745 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 12.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG: | 14.91 ± 5.312 | 12.92 ± 4.332 | 13.64 ± 4.035 | 12.38 ± 3.520 |
| IgA | 2.72 ± 1.321 | 2.73 ± 1.340 | 2.88 ± 1.363 | 2.68 ± 1.021 |
| IgM | 1.11 ± 0.683 | 1.05 ± 0.700 | 0.95 ± 0.610 | 1.02 ± 0.695 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 24.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | 15.01 ± 5.190 | 13.75 ± 4.783 | 13.79 ± 4.165 | 12.86 ± 3.725 |
| IgA | 2.79 ± 1.430 | 2.89 ± 1.460 | 2.98 ± 1.391 | 2.78 ± 1.091 |
| IgM | 1.07 ± 0.609 | 1.01 ± 0.686 | 0.89 ± 0.583 | 0.98 ± 0.656 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 36.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | 14.81 ± 5.217 | 13.54 ± 4.242 | 13.67 ± 3.934 | 12.65 ± 3.480 |
| IgA | 2.72 ± 1.378 | 2.89 ± 1.418 | 3.01 ± 1.420 | 2.86 ± 1.073 |
| IgM | 1.06 ± 0.630 | 1.01 ± 0.669 | 0.85 ± 0.541 | 0.95 ± 0.656 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 52
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | 15.21 ± 5.105 | 13.90 ± 4.087 | 14.32 ± 4.542 | 13.01 ± 3.723 |
| IgA | 2.82 ± 1.438 | 2.95 ± 1.596 | 3.17 ± 1.596 | 2.95 ± 1.159 |
| IgM | 1.08 ± 0.624 | 0.94 ± 0.645 | 0.82 ± 0.487 | 0.96 ± 0.670 |
Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 56
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | 14.82 ± 5.504 | 14.25 ± 4.435 | 14.25 ± 4.626 | 13.12 ± 4.507 |
| IgA | 2.95 ± 1.549 | 3.01 ± 1.459 | 2.89 ± 1.655 | 3.03 ± 1.164 |
| IgM | 1.11 ± 0.642 | 1.01 ± 0.601 | 0.95 ± 0.624 | 1.31 ± 0.869 |
Mean total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts.
| Cells per microliter | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Mean Absolute Total B Cell Count at Week 4 | 150 ± 126.9 | 236 ± 197.4 | 296 ± 243.8 | 229 ± 232.9 |
Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts.
| Cells per microliter | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Mean Absolute Total B Cell Count at Week 24 | 161 ± 125.8 | 184 ± 152.6 | 204 ± 158.3 | 151 ± 129.2 |
Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts.
| Cells per microliter | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Mean Absolute Total B Cell Count at Week 52 | 169 ± 121.9 | 167 ± 168.7 | 180 ± 170.7 | 119 ± 84.1 |
Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts.
| Cells per microliter | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Mean Absolute Total B Cell Count at Week 56 | 164 ± 113.3 | 129 ± 100.0 | 156 ± 127.1 | 104 ± 71.9 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | -0.51 ± 1.726 | -0.06 ± 1.361 | -0.15 ± 1.772 | -0.40 ± 1.025 |
| IgA | -0.11 ± 0.435 | -0.04 ± 0.431 | -0.01 ± 0.381 | -0.03 ± 0.268 |
| IgM | 0.00 ± 0.197 | -0.05 ± 0.194 | -0.04 ± 0.155 | -0.07 ± 0.116 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | -0.26 ± 1.760 | -0.16 ± 1.463 | -0.24 ± 1.657 | -0.45 ± 1.150 |
| IgA | -0.01 ± 0.205 | -0.04 ± 0.334 | 0.03 ± 0.447 | -0.03 ± 0.301 |
| IgM | 0.01 ± 0.195 | -0.09 ± 0.175 | -0.07 ± 0.192 | -0.08 ± 0.159 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | -0.36 ± 2.073 | -0.62 ± 1.827 | -0.72 ± 2.552 | -0.93 ± 1.640 |
| IgA | 0.00 ± 0.325 | -0.02 ± 0.360 | 0.06 ± 0.518 | -0.03 ± 0.340 |
| IgM | -0.01 ± 0.194 | -0.20 ± 0.301 | -0.18 ± 0.277 | -0.20 ± 0.250 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | -0.21 ± 2.318 | 0.11 ± 2.234 | -0.46 ± 2.912 | -0.57 ± 2.363 |
| IgA | 0.06 ± 0.332 | 0.14 ± 0.390 | 0.19 ± 0.565 | 0.04 ± 0.563 |
| IgM | -0.01 ± 0.264 | -0.23 ± 0.369 | -0.23 ± 0.321 | -0.25 ± 0.346 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | -0.15 ± 2.130 | 0.02 ± 2.487 | -0.43 ± 2.572 | -0.69 ± 2.189 |
| IgA | -0.02 ± 0.361 | 0.22 ± 0.453 | 0.24 ± 0.583 | 0.08 ± 0.459 |
| IgM | -0.04 ± 0.255 | -0.25 ± 0.416 | -0.25 ± 0.284 | -0.28 ± 0.392 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | 0.41 ± 2.898 | 0.29 ± 2.361 | 0.35 ± 2.688 | -0.31 ± 2.344 |
| IgA | 0.19 ± 0.420 | 0.32 ± 0.492 | 0.39 ± 0.767 | 0.18 ± 0.469 |
| IgM | -0.02 ± 0.235 | -0.25 ± 0.303 | -0.21 ± 0.318 | -0.33 ± 0.456 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
| gram per liter (g/L) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| IgG | 0.74 ± 2.907 | 1.06 ± 2.607 | 0.74 ± 1.987 | -0.40 ± 2.823 |
| IgA | 0.23 ± 0.468 | 0.48 ± 0.600 | 0.35 ± 0.488 | 0.26 ± 0.498 |
| IgM | 0.01 ± 0.266 | -0.15 ± 0.219 | -0.11 ± 0.225 | -0.21 ± 0.488 |
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.
| Cells per microliter | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Change From Baseline in Total B Cell Count at Week 4 | -5 ± 93.7 | 65 ± 146.6 | 87 ± 146.2 | 67 ± 109.1 |
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.
| Cells per microliter | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Change From Baseline in Total B Cell Count at Week 24 | 2 ± 98.1 | 5 ± 112.0 | 3 ± 103.2 | -7 ± 134.7 |
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.
| Cells per microliter | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Change From Baseline in Total B Cell Count at Week 52 | -14 ± 103.0 | -19 ± 133.3 | -14 ± 147.5 | -52 ± 215.7 |
Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.
| Cells per microliter | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Change From Baseline in Total B Cell Count at Week 56 | 7 ± 96.2 | -70 ± 138.2 | -75 ± 192.1 | -48 ± 85.8 |
BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity. Time to first severe flare, where a severe flare is defined as at least one BILAG A (Severe disease activity) score in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52-Week Treatment. It was measured using Kaplan-Meier (KM) estimates.
| Days | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Time to First Severe British Isles Lupus Assessment Group (BILAG) A Flare | NA (29.0 to 337.0) | NA (29.0 to 367.0) | NA (29.0 to 225.0) | NA (28.0 to 162.0) |
SRI-4 response was defined as greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor).
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52 in Serologically Active (SA) Subgroup | 28 | 38 | 29 | 34 |
SRI-6 response was defined as \>= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from 0(very well) to 100(very poor).
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6) at Week 52 in Serologically Active Subgroup | 17 | 25 | 23 | 23 |
BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity. A Moderate to Severe (BILAG A or 2B) flare is defined as at least one BILAG A (severe disease activity) grade or two BILAG B (moderate disease activity) grade in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52 week treatment. It was measured using Kaplan-Meier (KM) estimates.
| Days | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Time to First British Isles Lupus Assessment Group (BILAG) A or 2B Moderate to Severe Flare | NA (29.0 to 337.0) | NA (27.0 to 365.0) | NA (29.0 to 308.0) | NA (28.0 to 334.0) |
A participant has a flare-free status if no flare has been reported during the 52-week treatment period. Participants who discontinued treatment prior to Week 52, without having a flare are counted as not being flare free at Week 52. A flare was defined as either 1 or more new BILAG-2004 A (severe disease activity) or 2 or more new BILAG-2004 B (moderate disease activity) items compared to the previous visit. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With British Isles Lupus Assessment Group (BILAG) 2004 Flare-Free Status During the 52-Week Treatment Period | 41 | 35 | 37 | 33 |
A flare was defined as either 1 or more new BILAG-2004 A (severe disease activity) or 2 or more new BILAG-2004 B (moderate disease activity) items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG 2004 assessment.
| Annualized flare rate ratio | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Annualized Flare Rate | 0.15 (0.06 to 0.39) | 0.23 (0.09 to 0.59) | 0.13 (0.05 to 0.33) | 0.19 (0.07 to 0.51) |
Low disease activity is defined as SLEDAI-2K score \<=2. SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Low Disease Activity Status, Defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score of Less Than or Equal (<= ) 2 at Week 52 | 26 (15.5 to 31.6) | 32 (19.9 to 37.0) | 39 (25.1 to 43.0) | 28 (17.0 to 33.5) |
Low disease activity is defined as SLEDAI-2K score \<=2. SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). Clinical SLEDAI-2K score is equal to the SLEDAI-2K score from electronic case report form (eCRF) excluding the components 'Increased Deoxyribonucleic acid (DNA) Binding' and 'Low Complement'.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Low Disease Activity Status, Defined by Clinical Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score of Less Than or Equal (<= ) 2 at Week 52 | 42 (28.0 to 46.4) | 50 (34.3 to 53.0) | 52 (35.6 to 54.3) | 41 (27.2 to 45.5) |
SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).
| Units on a Scale | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Week 4 | -1 ± 1.9 | -1 ± 2.1 | 0 ± 1.9 | -1 ± 2.2 |
| Week 8 | -2 ± 3.1 | -2 ± 3.2 | -2 ± 3.0 | -2 ± 3.2 |
| Week 12 | -3 ± 3.8 | -3 ± 3.3 | -3 ± 3.2 | -3 ± 3.4 |
| Week 16 | -4 ± 3.7 | -3 ± 3.4 | -3 ± 3.4 | -3 ± 3.6 |
| Week 20 | -4 ± 4.1 | -4 ± 3.8 | -4 ± 3.4 | -4 ± 3.4 |
| Week 24 | -4 ± 4.0 | -4 ± 3.7 | -4 ± 3.6 | -3 ± 3.4 |
| Week 28 | -4 ± 3.9 | -4 ± 3.6 | -4 ± 3.5 | -4 ± 3.5 |
| Week 32 | -4 ± 4.0 | -4 ± 3.5 | -4 ± 3.7 | -4 ± 3.4 |
| Week 36 | -4 ± 4.3 | -5 ± 3.5 | -5 ± 3.6 | -4 ± 3.5 |
| Week 40 | -5 ± 4.1 | -5 ± 3.6 | -5 ± 3.8 | -4 ± 3.3 |
| Week 44 | -4 ± 4.0 | -5 ± 3.7 | -5 ± 3.9 | -4 ± 3.5 |
| Week 48 | -4 ± 4.1 | -5 ± 3.7 | -5 ± 3.8 | -5 ± 3.3 |
| Week 52 | -5 ± 4.0 | -5 ± 3.7 | -5 ± 3.7 | -5 ± 3.9 |
CLASI is an validated measurement instrument for lupus erythematosus developed for use in clinical studies that consists of separate scores for the activity of the disease (CLASI-A). The CLASI activity score is calculated on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI activity score ranges from 0-70, with higher scores indicating more severe skin disease. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70).
| Units on a Scale | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Week 2 | -1 ± 1.9 | -1 ± 1.6 | 0 ± 1.6 | 0 ± 1.2 |
| Week 4 | -1 ± 1.9 | -1 ± 3.5 | -1 ± 2.4 | -1 ± 2.2 |
| Week 8 | -2 ± 2.8 | -1 ± 4.2 | -1 ± 2.3 | -1 ± 2.5 |
| Week 12 | -2 ± 2.8 | -2 ± 3.3 | -2 ± 3.2 | -2 ± 2.7 |
| Week 16 | -2 ± 3.1 | -2 ± 3.9 | -2 ± 3.3 | -2 ± 2.7 |
| Week 20 | -3 ± 3.6 | -3 ± 4.4 | -3 ± 3.4 | -2 ± 2.9 |
| Week 24 | -3 ± 3.5 | -3 ± 4.7 | -3 ± 3.6 | -2 ± 2.7 |
| Week 28 | -3 ± 3.7 | -3 ± 4.6 | -3 ± 3.4 | -2 ± 2.7 |
| Week 32 | -3 ± 3.5 | -3 ± 4.4 | -3 ± 3.6 | -3 ± 3.2 |
| Week 36 | -3 ± 3.5 | -3 ± 4.6 | -3 ± 3.4 | -3 ± 3.6 |
| Week 40 | -3 ± 3.0 | -3 ± 4.6 | -3 ± 3.6 | -3 ± 3.8 |
| Week 44 | -3 ± 3.2 | -3 ± 4.5 | -3 ± 3.7 | -3 ± 3.8 |
| Week 48 | -3 ± 3.2 | -3 ± 4.7 | -3 ± 3.7 | -3 ± 3.9 |
| Week 52 | -3 ± 3.6 | -4 ± 4.8 | -3 ± 3.7 | -3 ± 4.0 |
BICLA response defined as participants meeting following criteria: \[1\] At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry (example: all A (severe disease) scores falling to B (moderate), C (mild), or D (no activity) and all B scores falling to C or D; \[2\] No new BILAG A or more than one new BILAG B scores; \[3\] No worsening of total SLEDAI-2K score from baseline; \[4\] No significant deterioration (=\<10%) in physician's global assessment and \[5\] No treatment failure (initiation of non-protocol treatment).
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Response Based on BILAG-Based Composite Lupus Assessment (BICLA) at Week 52 | 30 | 29 | 33 | 24 |
BILAG 2004 disease activity Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity.
| Units on a Scale | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Week 4 | -4 ± 5.8 | -4 ± 6.1 | -3 ± 6.3 | -4 ± 6.2 |
| Week 8 | -6 ± 6.0 | -5 ± 7.0 | -6 ± 6.3 | -6 ± 6.1 |
| Week 12 | -7 ± 6.7 | -7 ± 6.8 | -6 ± 7.0 | -6 ± 6.2 |
| Week 16 | -7 ± 6.9 | -7 ± 7.6 | -6 ± 6.8 | -6 ± 5.9 |
| Week 20 | -7 ± 6.8 | -7 ± 7.3 | -7 ± 7.6 | -6 ± 6.2 |
| Week 24 | -8 ± 6.9 | -7 ± 6.5 | -8 ± 7.7 | -6 ± 6.3 |
| Week 28 | -8 ± 6.7 | -8 ± 6.9 | -8 ± 7.4 | -7 ± 6.2 |
| Week 32 | -9 ± 6.7 | -8 ± 7.3 | -8 ± 7.9 | -7 ± 6.0 |
| Week 36 | -8 ± 7.1 | -8 ± 7.2 | -8 ± 7.4 | -7 ± 6.7 |
| Week 40 | -9 ± 6.8 | -8 ± 6.7 | -9 ± 7.7 | -7 ± 6.6 |
| Week 44 | -9 ± 7.2 | -9 ± 7.2 | -9 ± 7.9 | -7 ± 6.7 |
| Week 48 | -8 ± 7.1 | -8 ± 7.2 | -9 ± 7.6 | -7 ± 6.5 |
| Week 52 | -8 ± 7.0 | -9 ± 6.8 | -9 ± 7.8 | -7 ± 6.7 |
The Physician's Global Assessment of Disease Activity was recorded using the 100 millimeter horizontal Visual Analog Scale (VAS). Physician rated participant's disease activity on a scale ranged from 0-100 millimeter (mm), where 0 indicated no disease activity and 100 represented maximum disease activity.
| Millimeter | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Week 4 | -8 ± 11.7 | -8 ± 14.1 | -9 ± 13.4 | -9 ± 12.1 |
| Week 8 | -13 ± 16.2 | -14 ± 16.5 | -13 ± 15.5 | -14 ± 15.9 |
| Week 12 | -18 ± 17.4 | -18 ± 18.8 | -19 ± 18.3 | -18 ± 16.9 |
| Week 16 | -21 ± 17.6 | -20 ± 19.7 | -21 ± 18.7 | -19 ± 18.0 |
| Week 20 | -23 ± 19.2 | -21 ± 19.5 | -24 ± 17.9 | -20 ± 18.6 |
| Week 24 | -24 ± 17.8 | -24 ± 20.0 | -25 ± 19.2 | -21 ± 18.0 |
| Week 28 | -26 ± 17.6 | -26 ± 20.3 | -26 ± 18.6 | -24 ± 17.8 |
| Week 32 | -26 ± 17.8 | -26 ± 20.8 | -26 ± 19.0 | -26 ± 17.5 |
| Week 36 | -26 ± 17.9 | -26 ± 20.9 | -29 ± 18.3 | -26 ± 18.3 |
| Week 40 | -27 ± 16.9 | -27 ± 19.1 | -30 ± 19.7 | -25 ± 18.1 |
| Week 44 | -28 ± 16.6 | -28 ± 20.1 | -30 ± 20.7 | -26 ± 16.6 |
| Week 48 | -29 ± 16.5 | -29 ± 19.5 | -32 ± 18.8 | -28 ± 18.3 |
| Week 52 | -29 ± 16.2 | -31 ± 20.7 | -33 ± 19.2 | -27 ± 18.1 |
The 36-Item Short-Form Health Survey (SF-36) was a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) was based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0 - 100 (100 = highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100 = highest level of physical functioning).
| Units on a Scale | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Physical Component Summary Score at Week 4 | 1.2 ± 5.42 | 2.5 ± 7.40 | 3.5 ± 6.01 | 2.2 ± 5.86 |
| Physical Component Summary Score at Week 8 | 1.8 ± 6.35 | 3.5 ± 7.69 | 3.0 ± 6.61 | 2.2 ± 6.63 |
| Physical Component Summary Score at Week 12 | 2.4 ± 6.44 | 3.7 ± 7.71 | 4.2 ± 6.68 | 3.0 ± 6.99 |
| Physical Component Summary Score at Week 16 | 3.3 ± 7.04 | 4.0 ± 7.56 | 4.4 ± 5.81 | 3.4 ± 6.77 |
| Physical Component Summary Score at Week 24 | 3.4 ± 7.08 | 4.6 ± 7.57 | 5.4 ± 7.63 | 2.8 ± 7.15 |
| Physical Component Summary Score at Week 32 | 3.5 ± 8.03 | 3.8 ± 7.36 | 5.4 ± 7.24 | 3.8 ± 6.89 |
| Physical Component Summary Score at Week 40 | 4.2 ± 7.11 | 4.6 ± 7.97 | 5.7 ± 7.76 | 4.1 ± 8.59 |
| Physical Component Summary Score at Week 52 | 3.7 ± 8.32 | 5.4 ± 7.05 | 6.5 ± 8.58 | 4.8 ± 7.76 |
| Mental Component Summary Score at Week 4 | 3.9 ± 9.38 | 1.7 ± 9.25 | 1.9 ± 7.93 | 2.4 ± 7.68 |
| Mental Component Summary Score at Week 8 | 2.5 ± 8.59 | 2.2 ± 8.81 | 1.6 ± 8.48 | 3.6 ± 9.04 |
| Mental Component Summary Score at Week 12 | 3.1 ± 10.07 | 3.1 ± 8.45 | 0.8 ± 10.39 | 2.9 ± 8.89 |
| Mental Component Summary Score at Week 16 | 3.6 ± 9.84 | 2.5 ± 8.39 | 2.8 ± 9.39 | 2.9 ± 9.13 |
| Mental Component Summary Score at Week 24 | 2.9 ± 9.75 | 2.4 ± 8.41 | 3.4 ± 9.68 | 2.7 ± 8.87 |
| Mental Component Summary Score at Week 32 | 3.5 ± 8.55 | 1.8 ± 9.51 | 2.8 ± 9.71 | 4.3 ± 9.03 |
| Mental Component Summary Score at Week 40 | 4.5 ± 8.81 | 1.5 ± 10.55 | 3.2 ± 9.81 | 4.0 ± 9.85 |
| Mental Component Summary Score at Week 52 | 3.8 ± 9.45 | 1.7 ± 9.91 | 3.9 ± 11.21 | 4.6 ± 9.80 |
The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (perfect health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
| Units on a Scale | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Week 4 | 0.036 ± 0.1626 | 0.045 ± 0.1931 | 0.036 ± 0.1618 | 0.038 ± 0.1908 |
| Week 8 | 0.034 ± 0.2164 | 0.064 ± 0.2505 | 0.046 ± 0.1842 | 0.061 ± 0.1603 |
| Week 12 | 0.061 ± 0.2014 | 0.070 ± 0.2189 | 0.055 ± 0.1912 | 0.065 ± 0.1732 |
| Week 16 | 0.083 ± 0.1818 | 0.072 ± 0.2252 | 0.067 ± 0.2287 | 0.056 ± 0.1738 |
| Week 24 | 0.080 ± 0.1901 | 0.067 ± 0.2271 | 0.086 ± 0.2110 | 0.055 ± 0.1817 |
| Week 32 | 0.083 ± 0.1758 | 0.067 ± 0.2262 | 0.075 ± 0.2009 | 0.071 ± 0.1941 |
| Week 40 | 0.093 ± 0.1521 | 0.061 ± 0.1850 | 0.090 ± 0.1853 | 0.084 ± 0.2172 |
| Week 52 | 0.096 ± 0.2092 | 0.078 ± 0.2197 | 0.102 ± 0.2224 | 0.096 ± 0.2051 |
The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. The responses were used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 was the worst health you can imagine and 100 was the best health you can imagine.
| Millimeter | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Week 4 | 3 ± 16.8 | 2 ± 19.0 | 4 ± 17.6 | 4 ± 18.2 |
| Week 8 | 3 ± 18.8 | 6 ± 20.0 | 4 ± 14.5 | 6 ± 16.5 |
| Week 12 | 5 ± 19.7 | 6 ± 17.4 | 5 ± 17.2 | 4 ± 16.8 |
| Week 16 | 7 ± 19.3 | 5 ± 18.1 | 6 ± 18.5 | 4 ± 15.5 |
| Week 24 | 7 ± 18.7 | 5 ± 18.4 | 9 ± 20.4 | 4 ± 17.3 |
| Week 32 | 8 ± 17.2 | 4 ± 21.1 | 7 ± 17.8 | 7 ± 16.6 |
| Week 40 | 8 ± 18.1 | 6 ± 18.1 | 10 ± 19.5 | 8 ± 18.9 |
| Week 52 | 8 ± 19.9 | 8 ± 18.6 | 10 ± 21.3 | 10 ± 18.9 |
The Lupus QoL assessment is a 34 item questionnaire across 8 domains that is designed to find out how systemic lupus erythematosus (SLE) affects a participant's life. Domains include physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Participants indicate their responses on a 5-point Likert response format, where 4=never, 3=occasionally, 2= a good bit of the time, 1=most of the time, and 0=worst of the time. Summary scores can be calculated for all 8 domains. A LupusQoL score for each domain was reported on a 0 to 100 scale, with greater values indicating better health related QoL.
| Units on a scale | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Physical Health Week 4 | 1.9 ± 12.58 | 4.7 ± 17.68 | 4.0 ± 14.04 | 3.5 ± 13.43 |
| Physical Health Week 8 | 2.8 ± 15.20 | 6.3 ± 19.94 | 3.8 ± 17.64 | 4.6 ± 14.69 |
| Physical Health Week 12 | 4.8 ± 16.75 | 6.7 ± 19.78 | 5.6 ± 15.95 | 5.7 ± 14.94 |
| Physical Health Week 16 | 6.6 ± 17.45 | 6.1 ± 18.71 | 7.4 ± 17.61 | 6.2 ± 15.59 |
| Physical Health Week 24 | 6.9 ± 17.17 | 7.2 ± 18.59 | 8.4 ± 20.47 | 6.1 ± 13.63 |
| Physical Health Week 32 | 5.7 ± 16.82 | 6.7 ± 19.45 | 9.4 ± 17.21 | 7.0 ± 16.21 |
| Physical Health Week 40 | 7.6 ± 15.32 | 8.2 ± 17.38 | 9.6 ± 19.10 | 7.1 ± 17.98 |
| Physical Health Week 52 | 7.1 ± 20.39 | 9.0 ± 18.44 | 11.6 ± 19.88 | 7.9 ± 18.73 |
| Pain Week 4 | 3.6 ± 16.30 | 6.7 ± 21.81 | 9.0 ± 20.90 | 5.7 ± 16.26 |
| Pain Week 8 | 4.8 ± 18.71 | 9.9 ± 24.65 | 7.3 ± 21.76 | 6.7 ± 18.31 |
| Pain Week 12 | 7.5 ± 19.04 | 8.8 ± 24.00 | 9.8 ± 23.35 | 5.5 ± 14.73 |
| Pain Week 16 | 9.4 ± 18.58 | 8.3 ± 25.60 | 10.5 ± 26.33 | 6.9 ± 15.47 |
| Pain Week 24 | 9.4 ± 19.95 | 9.3 ± 24.31 | 13.0 ± 28.18 | 6.2 ± 17.02 |
| Pain Week 32 | 6.7 ± 23.74 | 9.2 ± 24.60 | 12.8 ± 22.87 | 8.7 ± 17.18 |
| Pain Week 40 | 11.0 ± 19.43 | 10.9 ± 23.68 | 15.3 ± 23.81 | 9.6 ± 20.51 |
| Pain Week 52 | 10.2 ± 21.37 | 12.9 ± 22.64 | 14.9 ± 26.11 | 9.6 ± 19.99 |
| Planning Week 4 | 4.8 ± 20.14 | 4.9 ± 19.64 | 5.4 ± 24.30 | 4.6 ± 18.73 |
| Planning Week 8 | 5.5 ± 23.32 | 8.4 ± 23.25 | 5.8 ± 25.14 | 3.9 ± 22.98 |
| Planning Week 12 | 7.8 ± 23.58 | 5.8 ± 23.39 | 6.8 ± 25.74 | 5.1 ± 20.55 |
| Planning Week 16 | 8.3 ± 21.65 | 5.3 ± 24.12 | 6.5 ± 28.00 | 6.3 ± 22.91 |
| Planning Week 24 | 7.9 ± 22.92 | 8.1 ± 23.55 | 11.5 ± 29.08 | 5.6 ± 21.79 |
| Planning Week 32 | 6.5 ± 24.82 | 7.6 ± 22.66 | 9.9 ± 25.90 | 6.9 ± 22.07 |
| Planning Week 40 | 9.0 ± 20.69 | 7.8 ± 23.19 | 11.6 ± 26.17 | 8.0 ± 23.52 |
| Planning Week 52 | 9.9 ± 22.38 | 7.0 ± 23.12 | 9.9 ± 28.29 | 10.5 ± 21.59 |
| Intimate Relationship Week 4 | 3.4 ± 26.11 | 1.6 ± 28.29 | 4.7 ± 24.06 | 3.2 ± 24.06 |
| Intimate Relationship Week 8 | 8.2 ± 30.31 | 4.2 ± 28.44 | 9.7 ± 29.10 | 3.7 ± 18.73 |
| Intimate Relationship Week 12 | 5.5 ± 27.31 | 4.7 ± 25.65 | 2.3 ± 30.37 | 6.4 ± 21.32 |
| Intimate Relationship Week 16 | 8.8 ± 26.77 | 1.6 ± 30.76 | 3.8 ± 32.46 | 4.2 ± 22.99 |
| Intimate Relationship Week 24 | 6.4 ± 30.12 | 2.1 ± 28.79 | 6.7 ± 30.76 | 5.3 ± 26.29 |
| Intimate Relationship Week 32 | 2.5 ± 28.77 | 1.3 ± 31.78 | 6.5 ± 29.41 | 1.4 ± 27.86 |
| Intimate Relationship Week 40 | 12.0 ± 27.59 | 6.6 ± 27.91 | 6.4 ± 32.53 | 7.8 ± 22.72 |
| Intimate Relationship Week 52 | 7.4 ± 26.48 | 4.4 ± 28.36 | 8.4 ± 29.58 | 8.9 ± 24.52 |
| Burden to Others Week 4 | 5.8 ± 23.83 | 5.2 ± 22.84 | 6.8 ± 24.85 | 2.2 ± 24.24 |
| Burden to Others Week 8 | 5.6 ± 22.42 | 9.3 ± 27.17 | 5.7 ± 25.80 | 8.0 ± 25.79 |
| Burden to Others Week 12 | 8.6 ± 25.86 | 6.7 ± 28.00 | 7.4 ± 25.93 | 7.3 ± 24.74 |
| Burden to Others Week 16 | 11.8 ± 26.17 | 8.1 ± 23.32 | 6.7 ± 25.80 | 7.4 ± 24.30 |
| Burden to Others Week 24 | 10.3 ± 28.68 | 9.0 ± 24.12 | 11.8 ± 27.15 | 5.8 ± 26.21 |
| Burden to Others Week 32 | 10.6 ± 29.42 | 6.8 ± 24.09 | 9.6 ± 27.14 | 8.4 ± 28.21 |
| Burden to Others Week 40 | 16.1 ± 25.07 | 12.4 ± 21.91 | 12.4 ± 28.74 | 12.1 ± 25.78 |
| Burden to Others Week 52 | 15.3 ± 26.96 | 10.7 ± 22.13 | 13.0 ± 30.04 | 10.5 ± 25.89 |
| Emotional Health Week 4 | 6.4 ± 15.37 | 4.7 ± 18.48 | 4.2 ± 18.45 | 1.8 ± 16.73 |
| Emotional Health Week 8 | 4.5 ± 15.15 | 7.0 ± 19.26 | 2.3 ± 19.51 | 5.3 ± 15.53 |
| Emotional Health Week 12 | 6.3 ± 17.23 | 7.6 ± 21.08 | 4.9 ± 20.99 | 4.7 ± 16.39 |
| Emotional Health Week 16 | 8.3 ± 15.86 | 7.5 ± 19.59 | 7.4 ± 18.56 | 6.2 ± 18.32 |
| Emotional Health Week 24 | 7.1 ± 17.31 | 5.6 ± 24.02 | 8.9 ± 20.97 | 4.3 ± 20.04 |
| Emotional Health Week 32 | 6.3 ± 17.07 | 4.3 ± 23.55 | 9.0 ± 22.66 | 6.0 ± 20.56 |
| Emotional Health Week 40 | 8.4 ± 16.08 | 8.3 ± 19.94 | 7.6 ± 21.52 | 6.7 ± 19.14 |
| Emotional Health Week 52 | 8.5 ± 17.43 | 6.4 ± 21.31 | 8.2 ± 22.77 | 7.6 ± 18.80 |
| Body Image Week 4 | 3.1 ± 17.70 | 8.4 ± 24.41 | 2.5 ± 24.60 | 4.0 ± 18.79 |
| Body Image Week 8 | 5.7 ± 18.37 | 7.5 ± 23.40 | -1.3 ± 27.06 | 6.5 ± 17.30 |
| Body Image Week 12 | 6.5 ± 18.57 | 7.1 ± 21.07 | 2.3 ± 26.86 | 6.6 ± 16.53 |
| Body Image Week 16 | 6.7 ± 18.10 | 7.6 ± 23.11 | -0.4 ± 25.31 | 5.7 ± 20.39 |
| Body Image Week 24 | 6.7 ± 20.84 | 10.2 ± 20.47 | 5.8 ± 27.31 | 6.7 ± 21.80 |
| Body Image Week 32 | 5.1 ± 20.08 | 8.1 ± 23.71 | 3.3 ± 24.99 | 5.8 ± 21.54 |
| Body Image Week 40 | 7.7 ± 14.11 | 8.2 ± 23.99 | 4.6 ± 26.67 | 9.0 ± 18.31 |
| Body Image Week 52 | 6.6 ± 16.92 | 9.8 ± 21.46 | 5.1 ± 27.30 | 7.8 ± 21.56 |
| Fatigue Week 4 | 4.4 ± 16.71 | 4.3 ± 18.98 | 6.2 ± 19.91 | 3.9 ± 17.08 |
| Fatigue Week 8 | 5.0 ± 19.22 | 7.1 ± 21.31 | 4.9 ± 20.61 | 4.5 ± 16.78 |
| Fatigue Week 12 | 6.7 ± 18.22 | 5.8 ± 21.30 | 7.3 ± 23.11 | 5.0 ± 16.08 |
| Fatigue Week 16 | 7.7 ± 17.61 | 6.6 ± 21.39 | 7.1 ± 24.16 | 4.1 ± 15.81 |
| Fatigue Week 24 | 7.5 ± 19.06 | 4.8 ± 23.34 | 9.0 ± 26.00 | 3.6 ± 14.20 |
| Fatigue Week 32 | 7.0 ± 19.20 | 3.7 ± 22.71 | 8.5 ± 22.96 | 4.1 ± 17.24 |
| Fatigue Week 40 | 11.3 ± 20.03 | 6.1 ± 25.28 | 11.0 ± 25.18 | 5.3 ± 16.73 |
| Fatigue Week 52 | 8.9 ± 21.15 | 4.5 ± 24.78 | 11.2 ± 22.56 | 6.7 ± 17.89 |
The PGIC is a self-rated scale that asks the participant to describe the change in activity limitations, symptoms, emotions, and overall quality of life (QoL) related to the participants painful condition on the following scale: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse). Number of participants in the PGIC categories of any improvement (that is PGIC scale score 1, 2 or 3), no change (that is PGIC scale score 4) and any worsening (that is PGIC scale score 5, 6 or 7) are reported.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Week 4 — Any Improvement | 69 | 78 | 81 | 71 |
| Week 4 — No Change | 33 | 27 | 23 | 34 |
| Week 4 — Any Worsening | 8 | 9 | 8 | 8 |
| Week 4 — Missing | 2 | 0 | 1 | 0 |
| Week 8 — Any Improvement | 80 | 81 | 85 | 75 |
| Week 8 — No Change | 22 | 18 | 19 | 28 |
| Week 8 — Any Worsening | 5 | 9 | 5 | 3 |
| Week 8 — Missing | 3 | 2 | 1 | 3 |
| Week 12 — Any Improvement | 78 | 82 | 81 | 77 |
| Week 12 — No Change | 23 | 13 | 15 | 20 |
| Week 12 — Any Worsening | 5 | 7 | 7 | 4 |
| Week 12 — Missing | 2 | 3 | 4 | 3 |
| Week 16 — Any Improvement | 75 | 81 | 87 | 79 |
| Week 16 — No Change | 23 | 13 | 16 | 15 |
| Week 16 — Any Worsening | 3 | 7 | 2 | 2 |
| Week 16 — Missing | 3 | 0 | 0 | 2 |
| Week 24 — Any Improvement | 67 | 77 | 87 | 73 |
| Week 24 — No Change | 23 | 12 | 7 | 17 |
| Week 24 — Any Worsening | 6 | 6 | 5 | 5 |
| Week 24 — Missing | 2 | 0 | 2 | 0 |
| Week 32 — Any Improvement | 70 | 70 | 80 | 72 |
| Week 32 — No Change | 16 | 15 | 8 | 13 |
| Week 32 — Any Worsening | 4 | 6 | 5 | 3 |
| Week 32 — Missing | 1 | 0 | 2 | 1 |
| Week 40 — Any Improvement | 67 | 69 | 80 | 73 |
| Week 40 — No Change | 19 | 12 | 7 | 9 |
| Week 40 — Any Worsening | 2 | 8 | 4 | 4 |
| Week 40 — Missing | 1 | 0 | 2 | 1 |
| Week 52 — Any Improvement | 66 | 64 | 76 | 64 |
| Week 52 — No Change | 14 | 18 | 6 | 13 |
| Week 52 — Any Worsening | 6 | 1 | 5 | 4 |
| Week 52 — Missing | 2 | 6 | 3 | 4 |
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status.
| Units on a scale | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Week 4 | 3 ± 8.0 | 2 ± 7.8 | 4 ± 9.1 | 3 ± 7.7 |
| Week 8 | 3 ± 8.7 | 3 ± 8.3 | 3 ± 9.1 | 5 ± 8.2 |
| Week 12 | 3 ± 10.0 | 4 ± 9.7 | 3 ± 9.7 | 4 ± 8.1 |
| Week 16 | 4 ± 9.8 | 3 ± 9.8 | 4 ± 10.2 | 3 ± 8.4 |
| Week 24 | 3 ± 9.9 | 4 ± 8.5 | 5 ± 10.3 | 3 ± 7.5 |
| Week 32 | 4 ± 9.6 | 4 ± 9.5 | 5 ± 9.7 | 4 ± 6.8 |
| Week 40 | 4 ± 8.8 | 3 ± 8.6 | 6 ± 9.9 | 4 ± 8.5 |
| Week 52 | 4 ± 9.9 | 4 ± 7.9 | 5 ± 9.7 | 5 ± 8.7 |
BILAG A or 2B flare is defined as at least one BILAG A grade or two BILAG B grade in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52 week treatment period. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to systemic lupus erythematosus (SLE), divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Change From Baseline in Prednisone Equivalent Corticosteroid (CS) Dose by >=25% to a Dose of <=7.5 Milligram Per Day (mg/Day), With no BILAG A or 2B Flare in Disease Activity at Week 52 | 19 | 23 | 20 | 21 |
Change From Baseline in Prednisone-equivalent CS Daily Dose at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 were reported.
| Milligram (mg) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Week 1 | 0.21 ± 1.443 | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Week 2 | 0.10 ± 1.206 | -0.07 ± 0.524 | 0.00 ± 0.000 | -0.13 ± 1.405 |
| Week 4 | 0.01 ± 1.267 | -0.45 ± 2.879 | -0.04 ± 0.739 | -0.15 ± 1.428 |
| Week 6 | -1.07 ± 3.563 | -0.64 ± 3.275 | -0.59 ± 2.095 | -0.70 ± 3.484 |
| Week 8 | -0.57 ± 2.588 | -1.24 ± 3.915 | -1.09 ± 3.640 | -1.02 ± 3.422 |
| Week 10 | -1.43 ± 3.985 | -2.04 ± 5.146 | -1.56 ± 4.137 | -2.50 ± 4.971 |
| Week 12 | -1.26 ± 3.260 | -1.85 ± 4.158 | -1.73 ± 4.574 | -1.97 ± 4.150 |
| Week 14 | -2.00 ± 4.569 | -2.70 ± 5.428 | -1.87 ± 4.489 | -2.76 ± 5.125 |
| Week 16 | -1.67 ± 4.427 | -2.70 ± 4.955 | -2.47 ± 5.365 | -2.40 ± 4.535 |
| Week 20 | -1.94 ± 4.054 | -2.82 ± 4.905 | -2.64 ± 5.489 | -2.53 ± 4.727 |
| Week 24 | -1.99 ± 4.228 | -2.64 ± 5.066 | -2.61 ± 5.568 | -2.34 ± 5.330 |
| Week 28 | -2.23 ± 4.439 | -2.97 ± 4.981 | -3.07 ± 6.068 | -2.46 ± 5.371 |
| Week 32 | -2.45 ± 4.584 | -3.13 ± 5.193 | -3.18 ± 6.161 | -2.44 ± 5.347 |
| Week 36 | -2.42 ± 4.835 | -3.31 ± 5.327 | -3.18 ± 6.136 | -2.37 ± 5.445 |
| Week 40 | -2.08 ± 6.149 | -3.21 ± 5.280 | -3.24 ± 6.218 | -2.67 ± 5.202 |
| Week 44 | -2.42 ± 4.833 | -3.21 ± 5.280 | -3.27 ± 6.254 | -2.56 ± 5.121 |
| Week 48 | -2.38 ± 4.895 | -3.22 ± 5.310 | -3.37 ± 6.265 | -2.62 ± 5.136 |
| Week 52 | -1.70 ± 5.470 | -2.94 ± 5.534 | -3.09 ± 5.981 | -2.63 ± 5.673 |
Number of Participants With Reduction From Baseline in Prednisone-equivalent Corticosteroid (CS) Daily Dose by \> 0 to 25%, \>25% to 50%, \>50% to 100% or an Increase at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 were reported.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| Reduction of dose by >0-25% Week 1 | 0 | 0 | 0 | 0 |
| Reduction of dose by >0-25% Week 2 | 1 | 2 | 0 | 0 |
| Reduction of dose by >0-25% Week 4 | 1 | 5 | 2 | 1 |
| Reduction of dose by >0-25% Week 6 | 3 | 4 | 3 | 4 |
| Reduction of dose by >0-25% Week 8 | 6 | 6 | 5 | 6 |
| Reduction of dose by >0-25% Week 10 | 0 | 3 | 4 | 5 |
| Reduction of dose by >0-25% Week 12 | 5 | 11 | 8 | 6 |
| Reduction of dose by >0-25% Week 14 | 2 | 2 | 4 | 5 |
| Reduction of dose by >0-25% Week 16 | 5 | 10 | 5 | 6 |
| Reduction of dose by >0-25% Week 20 | 5 | 10 | 5 | 5 |
| Reduction of dose by >0-25% Week 24 | 4 | 10 | 5 | 5 |
| Reduction of dose by >0-25% Week 28 | 2 | 8 | 5 | 4 |
| Reduction of dose by >0-25% Week 32 | 1 | 7 | 4 | 3 |
| Reduction of dose by >0-25% Week 36 | 1 | 5 | 4 | 3 |
| Reduction of dose by >0-25% Week 40 | 1 | 5 | 3 | 3 |
| Reduction of dose by >0-25% Week 44 | 1 | 5 | 3 | 3 |
| Reduction of dose by >0-25% Week 48 | 0 | 5 | 4 | 3 |
| Reduction of dose by >0-25% Week 52 | 1 | 5 | 4 | 4 |
| Reduction of dose by >25- 50% Week 1 | 0 | 0 | 0 | 0 |
| Reduction of dose by >25- 50% Week 2 | 0 | 0 | 0 | 0 |
| Reduction of dose by >25- 50% Week 4 | 1 | 2 | 1 | 0 |
| Reduction of dose by >25- 50% Week 6 | 4 | 1 | 2 | 0 |
| Reduction of dose by >25- 50% Week 8 | 5 | 9 | 6 | 5 |
| Reduction of dose by >25- 50% Week 10 | 7 | 6 | 4 | 10 |
| Reduction of dose by >25- 50% Week 12 | 14 | 9 | 10 | 15 |
| Reduction of dose by >25- 50% Week 14 | 7 | 6 | 2 | 8 |
| Reduction of dose by >25- 50% Week 16 | 16 | 12 | 9 | 16 |
| Reduction of dose by >25- 50% Week 20 | 13 | 11 | 8 | 14 |
| Reduction of dose by >25- 50% Week 24 | 12 | 9 | 8 | 13 |
| Reduction of dose by >25- 50% Week 28 | 14 | 12 | 9 | 16 |
| Reduction of dose by >25- 50% Week 32 | 15 | 11 | 8 | 16 |
| Reduction of dose by >25- 50% Week 36 | 15 | 13 | 6 | 15 |
| Reduction of dose by >25- 50% Week 40 | 15 | 15 | 6 | 16 |
| Reduction of dose by >25- 50% Week 44 | 15 | 15 | 6 | 16 |
| Reduction of dose by >25- 50% Week 48 | 15 | 14 | 6 | 17 |
| Reduction of dose by >25- 50% Week 52 | 16 | 12 | 7 | 17 |
| Reduction of dose by >50-100% Week 1 | 0 | 0 | 0 | 0 |
| Reduction of dose by >50-100% Week 2 | 0 | 0 | 0 | 1 |
| Reduction of dose by >50-100% Week 4 | 0 | 1 | 0 | 1 |
| Reduction of dose by >50-100% Week 6 | 1 | 1 | 0 | 1 |
| Reduction of dose by >50-100% Week 8 | 1 | 3 | 4 | 3 |
| Reduction of dose by >50-100% Week 10 | 2 | 3 | 3 | 4 |
| Reduction of dose by >50-100% Week 12 | 1 | 6 | 6 | 6 |
| Reduction of dose by >50-100% Week 14 | 5 | 6 | 7 | 7 |
| Reduction of dose by >50-100% Week 16 | 5 | 13 | 13 | 9 |
| Reduction of dose by >50-100% Week 20 | 7 | 13 | 14 | 11 |
| Reduction of dose by >50-100% Week 24 | 7 | 14 | 13 | 11 |
| Reduction of dose by >50-100% Week 28 | 9 | 14 | 15 | 11 |
| Reduction of dose by >50-100% Week 32 | 11 | 16 | 16 | 12 |
| Reduction of dose by >50-100% Week 36 | 10 | 17 | 18 | 11 |
| Reduction of dose by >50-100% Week 40 | 10 | 15 | 18 | 11 |
| Reduction of dose by >50-100% Week 44 | 10 | 15 | 18 | 10 |
| Reduction of dose by >50-100% Week 48 | 9 | 15 | 19 | 10 |
| Reduction of dose by >50-100% Week 52 | 9 | 17 | 19 | 12 |
| Increased from Baseline Week 1 | 1 | 0 | 0 | 0 |
| Increased from Baseline Week 2 | 2 | 0 | 0 | 0 |
| Increased from Baseline Week 4 | 2 | 1 | 1 | 0 |
| Increased from Baseline Week 6 | 1 | 1 | 0 | 0 |
| Increased from Baseline Week 8 | 2 | 1 | 1 | 0 |
| Increased from Baseline Week 10 | 1 | 1 | 0 | 0 |
| Increased from Baseline Week 12 | 1 | 1 | 1 | 0 |
| Increased from Baseline Week 14 | 1 | 0 | 0 | 0 |
| Increased from Baseline Week 16 | 1 | 1 | 1 | 0 |
| Increased from Baseline Week 20 | 0 | 0 | 0 | 0 |
| Increased from Baseline Week 24 | 0 | 0 | 0 | 0 |
| Increased from Baseline Week 28 | 0 | 0 | 0 | 1 |
| Increased from Baseline Week 32 | 0 | 0 | 0 | 1 |
| Increased from Baseline Week 36 | 0 | 0 | 0 | 1 |
| Increased from Baseline Week 40 | 1 | 0 | 0 | 1 |
| Increased from Baseline Week 44 | 0 | 0 | 0 | 1 |
| Increased from Baseline Week 48 | 0 | 0 | 0 | 1 |
| Increased from Baseline Week 52 | 2 | 0 | 0 | 2 |
Cumulative Prednisone-equivalent Corticosteroid (CS) Dose was calculated at Week 52.
| Milligrams | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Cumulative Prednisone Equivalent Corticosteroid (CS) Dose at Week 52 | 2267.66 ± 1507.652 | 2209.46 ± 1922.557 | 2137.70 ± 1618.688 | 2205.56 ± 1737.092 |
SRI-4 response was defined as greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor).
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to 7.5 mg Prednisone Equivalent Per Day or Less With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52 | 43 | 45 | 43 | 41 |
SRI-6 response was defined as \>= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor).
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to 7.5 mg Prednisone Equivalent Per Day or Less With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6) at Week 52 | 18 | 19 | 23 | 15 |
SRI-4 response was defined as greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from very well(0)-very poor(100).
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to 7.5 mg Prednisone Equivalent Per Day or Less With Response Based on SRI-4 at Week 52 in Serologically Active Subgroup | 21 | 25 | 22 | 25 |
Lupus low disease activity state will be measured as: SLEDAI-2K \<= 4; No activity in any major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever); No new features of disease activity compared with the previous assessment; Prednisone-equivalent \<= 7.5 milligram per day; Unchanged background immunosuppressive therapy.
| Participants | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID |
|---|---|---|---|---|
| DBPC Period: Number of Participants With Lupus Low Disease Activity State (LLDAS) at Week 52 | 29 | 32 | 35 | 29 |
Collected over Double-Blind Placebo-Controlled: Baseline up to Week 56 Long-Term Extension: Up to Week 108. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBPC Period: Placebo | 0/117 (0%) | 10/117 (8.5%) | 76/117 (65%) |
| DBPC Period: M2951 25 mg QD | 1/118 (0.8%) | 13/118 (11%) | 85/118 (72%) |
| DBPC Period: M2951 75 mg QD | 1/117 (0.9%) | 11/117 (9.4%) | 75/117 (64.1%) |
| DBPC Period: M2951 50 mg BID | 0/117 (0%) | 9/117 (7.7%) | 78/117 (66.7%) |
| LTE: Placebo/ M2951 50 mg BID | 0/62 (0%) | 5/62 (8.1%) | 22/62 (35.5%) |
| LTE Period: M2951 25 mg QD/ M2951 50 mg BID | 0/69 (0%) | 5/69 (7.2%) | 34/69 (49.3%) |
| LTE Period: M2951 75 mg QD/ M2951 50 mg BID | 0/80 (0%) | 5/80 (6.3%) | 35/80 (43.8%) |
| LTE: M2951 50 mg BID/ M2951 50 mg BID | 0/72 (0%) | 7/72 (9.7%) | 23/72 (31.9%) |
| Event | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID | LTE: Placebo/ M2951 50 mg BID | LTE Period: M2951 25 mg QD/ M2951 50 mg BID | LTE Period: M2951 75 mg QD/ M2951 50 mg BID | LTE: M2951 50 mg BID/ M2951 50 mg BID |
|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/117 | 0/118 | 0/117 | 0/117 | 0/62 | 2/69 | 0/80 | 0/72 |
| Non-cardiac chest painGeneral disorders | 0/117 | 2/118 | 0/117 | 2/117 | 0/62 | 0/69 | 0/80 | 0/72 |
| Otitis mediaInfections and infestations | 0/117 | 0/118 | 2/117 | 0/117 | 0/62 | 0/69 | 0/80 | 0/72 |
| HeadacheNervous system disorders | 2/117 | 1/118 | 0/117 | 0/117 | 0/62 | 0/69 | 0/80 | 0/72 |
| HepatitisHepatobiliary disorders | 0/117 | 1/118 | 0/117 | 0/117 | 1/62 | 0/69 | 0/80 | 0/72 |
| OsteomyelitisInfections and infestations | 1/117 | 0/118 | 0/117 | 0/117 | 1/62 | 0/69 | 0/80 | 0/72 |
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 1/117 | 0/118 | 0/117 | 0/117 | 1/62 | 0/69 | 0/80 | 0/72 |
| AnaemiaBlood and lymphatic system disorders | 0/117 | 0/118 | 0/117 | 0/117 | 1/62 | 0/69 | 0/80 | 0/72 |
| LymphadenitisBlood and lymphatic system disorders | 0/117 | 0/118 | 0/117 | 0/117 | 1/62 | 0/69 | 0/80 | 0/72 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/117 | 0/118 | 0/117 | 0/117 | 1/62 | 0/69 | 0/80 | 0/72 |
| Event | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID | LTE: Placebo/ M2951 50 mg BID | LTE Period: M2951 25 mg QD/ M2951 50 mg BID | LTE Period: M2951 75 mg QD/ M2951 50 mg BID | LTE: M2951 50 mg BID/ M2951 50 mg BID |
|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 16/117 | 21/118 | 26/117 | 21/117 | 4/62 | 7/69 | 7/80 | 6/72 |
| HeadacheNervous system disorders | 20/117 | 17/118 | 19/117 | 17/117 | 1/62 | 7/69 | 2/80 | 5/72 |
| DiarrhoeaGastrointestinal disorders | 11/117 | 12/118 | 17/117 | 10/117 | 3/62 | 5/69 | 7/80 | 2/72 |
| NasopharyngitisInfections and infestations | 8/117 | 13/118 | 15/117 | 7/117 | 5/62 | 5/69 | 7/80 | 5/72 |
| Upper respiratory tract infectionInfections and infestations | 12/117 | 15/118 | 6/117 | 8/117 | 3/62 | 6/69 | 3/80 | 0/72 |
| Alanine aminotransferase increasedInvestigations | 3/117 | 8/118 | 6/117 | 6/117 | 5/62 | 4/69 | 1/80 | 2/72 |
| LymphopeniaBlood and lymphatic system disorders | 9/117 | 4/118 | 6/117 | 2/117 | 0/62 | 0/69 | 0/80 | 0/72 |
| NauseaGastrointestinal disorders | 7/117 | 8/118 | 9/117 | 5/117 | 0/62 | 0/69 | 0/80 | 0/72 |
| Influenza like illnessGeneral disorders | 5/117 | 7/118 | 9/117 | 7/117 | 4/62 | 0/69 | 2/80 | 0/72 |
| Back PainMusculoskeletal and connective tissue disorders | 3/117 | 4/118 | 5/117 | 9/117 | 0/62 | 0/69 | 0/80 | 0/72 |
| Age, Continuous(Years) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID | Total |
|---|---|---|---|---|---|
| Mean | 40.2 ± 12.49 | 38.8 ± 12.45 | 41.5 ± 12.52 | 42.2 ± 11.78 | 40.7 ± 12.34 |
| Sex: Female, Male(Participants) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID | Total |
|---|---|---|---|---|---|
| Female | 110 | 112 | 111 | 112 | 445 |
| Male | 7 | 6 | 6 | 5 | 24 |
| Ethnicity (NIH/OMB)(Participants) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 45 | 51 | 47 | 42 | 185 |
| Not Hispanic or Latino | 72 | 67 | 70 | 75 | 284 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DBPC Period: Placebo | DBPC Period: M2951 25 mg QD | DBPC Period: M2951 75 mg QD | DBPC Period: M2951 50 mg BID | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 23 | 17 | 21 | 13 | 74 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 12 | 11 | 12 | 45 |
| White | 66 | 73 | 68 | 83 | 290 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 18 | 16 | 17 | 9 | 60 |
Showing the first 100 of 157 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evobrutinib
Lupus Erythematosus, Systemic →
EMD Serono Research & Development Institute, Inc. →